J&J Gains on Claims Its Booster Shot Raises Immunity Against Covid By Investing.com
By Dhirendra Tripathi
Investing.com – Johnson & Johnson (NYSE:) stock traded more than 1% up in Tuesday’s premarket on encouraging results from a phase-III real-world study on a booster dose of its Covid-19 vaccine.
According to the company, its booster shot can be administered up to 94% after two months. According to it, the booster can increase antibody levels up to four to six times when administered two months after one dose.
The company stated that boosters given six months following the initial shot seem to provide even greater protection. According to the company, all increases were made regardless of one’s age.
J&J’s Covid-19 vaccine is the only one approved by western economies that is administered with a single dose.
Around 14.8 million Americans have received the company’s single-dose vaccine so far. The study included 390,000 people who received the J&J Covid-19 vaccine.
An advisory committee on Friday recommended Pfizer (NYSE:) booster shots to people 65 years and older, along with other vulnerable population groups. The Food and Drug Administration will make a final decision within the next 24 hours. A plan supported by the Biden administration, Covid-19 booster shot widely was rejected by the panel.
The administration’s plans on boosters have received flak from various quarters, notably the World Health Organization, as much of the world is still unvaccinated, allowing the virus to spread and mutate freely in those countries.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Trading the financial markets is among the most risky investment options. Please make sure you are fully aware of all the costs and risks involved.